ROCK2 and cancer: These results suggested that ROCK2-mediated inhibition of ferroptosis contributes to Pemigatinib resistance in CCA cells through the UBA52–Drp1 axis; targeting of ROCK2 with the inhibitor—belumosudil—enhanced the sensitivity of these cancer cells to Pemigatinib (Fig. 8).